We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Collaboration to Develop NMR Hypersense Technology

By Biotechdaily staff writers
Posted on 17 Oct 2005
Print article
Oxford Instruments Molecular Biotools (OIMBL, Oxon, UK) has entered into three landmark collaborative agreements with Pfizer Global R&D (Sandwich, UK), Queen Mary and Westfield College, University of London (London, UK), and the University of Birmingham Institute for Cancer Studies (UK). These agreements allow for the development of sophisticated and innovative applications in nuclear magnetic resonance (NMR) technology, utilizing the dramatic enhancement in the signal-to-noise ratio provided by HyperSense.

HyperSense is a novel in vitro dynamic nuclear polarization (DNP) polarizer capable of amplifying the baseline signal-to-noise ratio of NMR systems by a factor of up to 10,000 for 1D NMR spectral analysis. HyperSense is the first commercial product of its kind that enables scientists to attain an excellent level of information quality and richness, while opening up the field of practical NMR analysis to totally new areas of research. It is a modular instrument that will attach to any traditional NMR system, to deliver polarization-enhanced samples using a solid-state dynamic nuclear polarization (DNP) technique recently licensed from GE Healthcare (Waukesha, WI, USA).

The collaborators, representing some of the major NMR groups across academia and industry in the United Kingdom, will evaluate different aspects of the use of the enhanced levels of signal-to-noise ratio provided by HyperSense, in applications across life science research, pharmaceuticals, and chemistry.

At the biomolecular NMR spectroscopy laboratory at the University of Birmingham, Prof. Michael Overduin and Dr. Ulrich Günther of the CRC Institute for Cancer Studies (Birmingham, UK) will use HyperSense to conduct additional studies to identify biologic markers for different types of cancer and to develop new methods for determining the kinetics and dynamics of protein-ligand interactions.

The diversity of NMR research applications directly reflects the flexibility of applications for HyperSense. By providing the information richness of NMR and enhancing the signal-to-noise ratio by up to 10,000 fold, this technique avoids time-consuming and labor-intensive enrichment processes that were once a requisite.


Related Links:
Oxford Instruments Molecular Biotools
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.